Sign in or create an account to add this stock to your watchlist.
About Evolent Health (NYSE:EVH)
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management. Its services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Industry, Sector and Symbol
Industry Management services
Sub-IndustryN/A
SectorComputer and Technology
SymbolNYSE:EVH
CUSIPN/A
Phone571-389-6000
Debt
Debt-to-Equity Ratio0.12
Current Ratio2.88
Quick Ratio2.88
Price-To-Earnings
Trailing P/E Ratio-27.86
Forward P/E Ratio-59.09
P/E GrowthN/A
Sales & Book Value
Annual Sales$434.95 million
Price / Sales3.49
Cash FlowN/A
Price / CashN/A
Book Value$13.52 per share
Price / Book1.44
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-60,660,000.00
Net Margins-12.11%
Return on Equity-2.16%
Return on Assets-1.73%
Miscellaneous
Employees2,600
Outstanding Shares77,940,000
Evolent Health (NYSE:EVH) Frequently Asked Questions
What is Evolent Health's stock symbol?
Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."
How were Evolent Health's earnings last quarter?
Evolent Health (NYSE:EVH) released its quarterly earnings results on Wednesday, May, 9th. The technology company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The technology company earned $139.70 million during the quarter, compared to analyst estimates of $140.89 million. Evolent Health had a negative return on equity of 2.16% and a negative net margin of 12.11%. Evolent Health's quarterly revenue was up 31.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.14) EPS. View Evolent Health's Earnings History.
What price target have analysts set for EVH?
12 equities research analysts have issued 1 year target prices for Evolent Health's shares. Their forecasts range from $20.00 to $30.00. On average, they anticipate Evolent Health's share price to reach $25.3333 in the next year. View Analyst Ratings for Evolent Health.
What are Wall Street analysts saying about Evolent Health stock?
Here are some recent quotes from research analysts about Evolent Health stock:
- 1. According to Zacks Investment Research, "Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. " (5/15/2018)
- 2. Cantor Fitzgerald analysts commented, "Health plan acquisitions. Over the past few months, EVH has announced two small health plan acquisitions that should help to grow its platform and operations revenue and add a new line of business. The acquisition of Premier in Dayton, OH, is somewhat more concerning for investors as the regulatory filings show that the plan is in a loss position. However, many provider-owned health plans typically show losses in regulatory filings. The company is expecting to receive better pricing from Premier and that it is not considering additional health plan acquisitions, at least in the near term. However, it will continue to use capital to align the company with customers. Note, our estimates do not yet reflect the health plan acquisitions." (12/3/2017)
Who are some of Evolent Health's key competitors?
Who are Evolent Health's key executives?
Evolent Health's management team includes the folowing people:
- Mr. Frank J. Williams, Co-Founder, CEO & Director (Age 51)
- Mr. Seth Blackley, Co-Founder & Pres (Age 39)
- Mr. Steven J. Wigginton, Former Exec. VP (Age 52)
- Mr. Tom Peterson III, Co-Founder & COO (Age 48)
- Mr. Nicholas McGrane, Chief Financial Officer (Age 50)
When did Evolent Health IPO?
(EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.
Has Evolent Health been receiving favorable news coverage?
Media stories about EVH stock have been trending somewhat positive on Tuesday, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Evolent Health earned a daily sentiment score of 0.09 on Accern's scale. They also gave press coverage about the technology company an impact score of 46.60 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Evolent Health's major shareholders?
Evolent Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.85%), Millennium Management LLC (4.11%), Blair William & Co. IL (3.20%), Elk Creek Partners LLC (3.03%), Eagle Asset Management Inc. (2.57%) and Dimensional Fund Advisors LP (2.51%). Company insiders that own Evolent Health stock include Board Co Advisory, Chad Pomeroy, Cheryl Scott, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Michael D'amato, Nicholas Mcgrane, Seth Blackley, Steve Wigginton, Thomas Peterson III, Tpg Growth Ii Advisors, Inc, Unitedhealth Group Inc and Upmc. View Institutional Ownership Trends for Evolent Health.
Which institutional investors are selling Evolent Health stock?
EVH stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Point72 Asset Management L.P., Thrivent Financial for Lutherans, Dowling & Yahnke LLC, Eagle Asset Management Inc., Trellus Management Company LLC, PNC Financial Services Group Inc. and Teacher Retirement System of Texas. Company insiders that have sold Evolent Health company stock in the last year include Frank J Williams, Kenneth A Samet, Nicholas Mcgrane, Seth Blackley, Steve Wigginton, Thomas Peterson III, Tpg Growth Ii Advisors, Inc and Unitedhealth Group Inc. View Insider Buying and Selling for Evolent Health.
Which institutional investors are buying Evolent Health stock?
EVH stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Elk Creek Partners LLC, Millennium Management LLC, Thornburg Investment Management Inc., Kornitzer Capital Management Inc. KS, Dimensional Fund Advisors LP, State of Wisconsin Investment Board and Oppenheimer & Co. Inc.. View Insider Buying and Selling for Evolent Health.
How do I buy shares of Evolent Health?
Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evolent Health's stock price today?
One share of EVH stock can currently be purchased for approximately $19.50.
How big of a company is Evolent Health?
Evolent Health has a market capitalization of $1.52 billion and generates $434.95 million in revenue each year. The technology company earns $-60,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Evolent Health employs 2,600 workers across the globe.
How can I contact Evolent Health?
Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.
MarketBeat Community Rating for Evolent Health (EVH)
MarketBeat's community ratings are surveys of what our community members think about Evolent Health and other stocks. Vote "Outperform" if you believe EVH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Evolent Health (NYSE:EVH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Evolent Health in the last 12 months. Their average twelve-month price target is $25.3333, suggesting that the stock has a possible upside of 29.91%. The high price target for EVH is $30.00 and the low price target for EVH is $20.00. There are currently 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $25.3333 | $25.3333 | $27.40 | $28.00 |
| Price Target Upside: | 29.91% upside | 72.92% upside | 101.47% upside | 151.12% upside |
Evolent Health (NYSE:EVH) Consensus Price Target History
Evolent Health (NYSE:EVH) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Evolent Health (NYSE:EVH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Evolent Health (NYSE EVH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.82%
Evolent Health (NYSE EVH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/10/2018 | Seth Blackley | President | Sell | 64,398 | $17.63 | $1,135,336.74 | |  |
| 5/8/2018 | Seth Blackley | President | Sell | 85,596 | $17.08 | $1,461,979.68 | | |
| 3/1/2018 | Unitedhealth Group Inc | Director | Sell | 3,040,000 | $13.70 | $41,648,000.00 | | |
| 8/3/2017 | Frank J. Williams | CEO | Sell | 16,300 | $23.73 | $386,799.00 | | |
| 8/1/2017 | Steve Wigginton | CEO | Sell | 6,000 | $24.64 | $147,840.00 | | |
| 7/24/2017 | Thomas Peterson III | COO | Sell | 40,540 | $26.00 | $1,054,040.00 | | |
| 7/10/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $25.42 | $42,375.14 | | |
| 7/6/2017 | Frank J. Williams | CEO | Sell | 16,300 | $24.76 | $403,588.00 | | |
| 7/3/2017 | Steve Wigginton | CEO | Sell | 6,000 | $25.07 | $150,420.00 | | |
| 6/28/2017 | Tpg Growth Ii Advisors, Inc. | Insider | Sell | 4,279,325 | $25.87 | $110,706,137.75 | | |
| 6/15/2017 | Seth Blackley | President | Sell | 15,000 | $25.22 | $378,300.00 | | |
| 6/12/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $24.58 | $40,974.86 | | |
| 6/7/2017 | Nicholas Mcgrane | CFO | Sell | 10,495 | $26.95 | $282,840.25 | | |
| 6/6/2017 | Kenneth A. Samet | Director | Sell | 4,000 | $25.75 | $103,000.00 | | |
| 6/6/2017 | Steve Wigginton | CEO | Sell | 959 | $25.75 | $24,694.25 | | |
| 5/19/2017 | Cheryl Scott | Director | Sell | 5,477 | $23.51 | $128,764.27 | | |
| 5/19/2017 | Frank J. Williams | CEO | Sell | 114,865 | $24.30 | $2,791,219.50 | | |
| 5/19/2017 | Jonathan Weinberg | General Counsel | Sell | 17,230 | $24.30 | $418,689.00 | | |
| 5/19/2017 | Nicholas Mcgrane | CFO | Sell | 47,508 | $24.30 | $1,154,444.40 | | |
| 5/19/2017 | Thomas Peterson III | COO | Sell | 57,433 | $24.30 | $1,395,621.90 | | |
| 5/19/2017 | Tpg Growth Ii Advisors, Inc. | Insider | Sell | 3,081,760 | $24.30 | $74,886,768.00 | | |
| 5/19/2017 | Upmc | Major Shareholder | Sell | 2,333,333 | $24.30 | $56,699,991.90 | 6,434,283 | |
| 5/15/2017 | Seth Blackley | President | Sell | 15,000 | $25.00 | $375,000.00 | 760,944 | |
| 5/15/2017 | Thomas Peterson III | COO | Sell | 83,108 | $24.99 | $2,076,868.92 | 341,092 | |
| 5/10/2017 | Nicholas Mcgrane | Insider | Sell | 1,667 | $24.28 | $40,474.76 | 132,047 | |
| 5/10/2017 | Thomas Peterson III | COO | Sell | 18,604 | $25.00 | $465,100.00 | 395,587 | |
| 5/4/2017 | Frank J Williams | CEO | Sell | 16,300 | $23.55 | $383,865.00 | 1,284,943 | |
| 5/3/2017 | Jonathan Weinberg | General Counsel | Sell | 15,000 | $23.85 | $357,750.00 | 86,385 | |
| 5/1/2017 | Steve Wigginton | CEO | Sell | 6,000 | $23.10 | $138,600.00 | 364,704 | |
| 5/1/2017 | Upmc | Major Shareholder | Sell | 403,644 | $19.53 | $7,883,167.32 | 8,767,616 | |
| 4/19/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $22.52 | $37,540.84 | 132,047 | |
| 4/17/2017 | Seth Blackley | President | Sell | 15,000 | $21.48 | $322,200.00 | 794,602 | |
| 4/6/2017 | Frank J Williams | CEO | Sell | 16,300 | $22.03 | $359,089.00 | 1,301,243 | |
| 4/3/2017 | Steve Wigginton | CEO | Sell | 6,000 | $23.15 | $138,900.00 | 364,704 | |
| 3/31/2017 | Upmc | Major Shareholder | Sell | 2,690,961 | $19.53 | $52,554,468.33 | 9,171,260 | |
| 3/30/2017 | Seth Blackley | President | Sell | 15,000 | $21.19 | $317,850.00 | 807,228 | |
| 3/28/2017 | Board Co Advisory | Major Shareholder | Sell | 2,118,078 | $19.53 | $41,366,063.34 | 6,246,245 | |
| 3/24/2017 | Nicholas Mcgrane | CFO | Sell | 7,034 | $22.50 | $158,265.00 | 137,414 | |
| 1/30/2017 | Seth Blackley | President | Sell | 15,000 | $17.58 | $263,700.00 | 824,848 | |
| 1/17/2017 | Seth Blackley | President | Sell | 30,000 | $17.98 | $539,400.00 | 854,848 | |
| 11/14/2016 | Michael D'amato | Director | Buy | 10,000 | $17.18 | $171,800.00 | 18,183 | |
| 9/22/2016 | Board Co Advisory | Major Shareholder | Sell | 317,712 | $22.50 | $7,148,520.00 | 4,128,167 | |
| 9/14/2016 | Board Co Advisory | Major Shareholder | Sell | 1,936,529 | $22.50 | $43,571,902.50 | 4,445,879 | |
| 9/14/2016 | Chad Pomeroy | Insider | Sell | 55,180 | $21.54 | $1,188,577.20 | 286,370 | |
| 9/14/2016 | Frank J Williams | CEO | Sell | 251,481 | $21.54 | $5,416,900.74 | 1,304,799 | |
| 9/14/2016 | Jonathan Weinberg | General Counsel | Sell | 10,339 | $21.54 | $222,702.06 | 76,245 | |
| 9/14/2016 | Nicholas Mcgrane | CFO | Sell | 21,205 | $21.54 | $456,755.70 | 136,495 | |
| 9/14/2016 | Seth Blackley | President | Sell | 167,672 | $21.54 | $3,611,654.88 | 869,848 | |
| 9/14/2016 | Thomas Peterson III | COO | Sell | 72,827 | $21.54 | $1,568,693.58 | 377,623 | |
| 6/10/2015 | Gary Piefer | Insider | Buy | 2,000 | $17.00 | $34,000.00 | | |
(Data available from 1/1/2013 forward)
Evolent Health (NYSE EVH) News Headlines
| Source: |
|
Evolent Health (NYSE:EVH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Evolent Health (NYSE:EVH) Income Statement, Balance Sheet and Cash Flow Statement
Evolent Health (NYSE EVH) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
